ITA ENG HOME WHO WE ARE THERAPEUTIC AREAS INNOVATION & RESEARCH WORK WITH US ETHICS AND COMPLIANCE PHARMACOVIGILANCE AREA UROLOGICAL BENIGN PROSTATIC HYPERTROPHY Approximately 50% of men over 60 and 80% of men over 80 have symptoms attributable to benign prostatic hypertrophy (BPH). Benign prostatic hyperplasia (BPH) is a condition characterized by the enlargement of the prostate gland that occurs with advancing age. The symptoms are of two types: the urinary ones of obstructive type and those of the irritative type. Obstructive problems include difficulty in starting urination, intermittent flow emission, incomplete emptying of the bladder, weak urinary flow and effort in urination. Irritative symptoms include frequency of urinating, nocturia, that is, an increased need during the night, urge to urinate (the urgent need to empty the bladder) and burning pain when urinating. Until a few years ago, when the disease was prevalent in surgery, 20% of men over 50 underwent partial resection of the prostate. Today, thanks to drugs for the treatment of BPH in many cases it is possible to avoid or, at least, postpone the intervention by improving the symptoms. Harrison. Principles of internal medicine. 16th edition. PHARMACOVIGILANCE Pharmacovigilance: what does it mean to monitor a drug? FARMINDUSTRIA Guidelines for Scientific Information ETHICS AND COMPLIANCE We are convinced that placing integrity and ethics in our actions is our strength and the key to ever greater success. WHO WE ARE History Values and Mission Contact us Privacy Preferenze cookie THERAPEUTIC AREAS Allergological Area Antibiotic Area Cardiovascular area Pain area Gastroenterological area Respiratory area Urological area Our products INNOVATION & RESEARCH WORK WITH US Open positions Submit your resume PHARMACOVIGILANCE MALESCI Istituto Farmacobiologico SpA - Registered office: Bagno a Ripoli - Via Lungo l'Ema, 7 - 50012 Bagno a Ripoli (Fi) Tel. 05564941 - Fax 055/645599 - Tax code and VAT number: 00408570489 - Company registration number: FI-55452 - Capital IV: € 255,000 - Company subject to the management and coordination of A. Menarini Industrie Farmaceutiche Riunite Srl Copyright 2021 Malesci ITALY - All rights reserved - VAT number: 00408570489 Our site uses cookies. If you close the banner BY CLICKING ON THE X, only technical cookies will be installed on your device, ie "strictly necessary" cookies (without which the site would not work), as well as, where present, "performance cookies", which perform aggregate statistics on use of the site. On the contrary, all other categories of cookies that may be present on the site, ie "functional cookies", which allow better navigation usability (eg, remembering the settings selected by the user during previous visits to the site), the "cookies of targeted advertising "and" social media "cookies, which allow you to submit content, including advertising, in line with the preferences expressed by you in the context of surfing the net on this and other sites, automatically detected (profiling), they will be installed only by clicking "ACCEPT". If you want to know more click on COOKIE POLICY. To view the list of cookies actually present on the site, customize the types of cookies desired and third parties who could access the data, click on "ADDITIONAL INFORMATION". ACCETTO INFORMAZIONI AGGIUNTIVE